Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor
- PMID: 27629667
- PMCID: PMC5023342
Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor
Erratum in
-
Correction.Can Fam Physician. 2016 Nov;62(11):877. Can Fam Physician. 2016. PMID: 28661863 Free PMC article. No abstract available.
References
-
- Canadian Diabetes Association [website] About diabetes. Toronto, ON: Canadian Diabetes Association; 2016. Available from: www.diabetes.ca/about-diabetes/types-of-diabetes. Accessed 2016 Feb 8.
-
- Health Canada [website] Drugs and health products. Ottawa, ON: Health Canada; 2016. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_invokan.... Accessed 2016 Apr 30.
-
- Scheen AS. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf. 2015;14(12):1879–904. Epub 2015 Oct 29. - PubMed
-
- Health Canada [website] Forxiga, Invokana. Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. Ottawa, ON: Health Canada; 2015. Available from: www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/53892a-en.... Accessed 2016 Apr 30.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical